We were unable to process your request. Please try again later.if you continue to have this issue please contact [email protected].
Back to Healio
“To our knowlege, this is the frist study to investigate the association between achieving BMI < 25 kg/m2 and long-term predicted ASCVD risk among individuals with obesity or overweight," Lixin Guo, MD, PhD, of the department of endocrinology, Beijing Hospital, National Center of Gerontology and the Institute of Geriatric Medicine at the Chinese Academy of Medical Sciences in Beijing, and colleagues wrote. "This study found that participants who achieved BMI < 25 kg/m2 after 52 or 72 weeks of tirzepatide or placebo treatment had considerably greater reductions in 10-year predicted ASCVD risk compared with those who did not."
SURMOUNT-1, SURMOUNT-3 and SURMOUNT-CN were all phase 3, multicenter, randomized, double-blind, placebo-controlled trials. In SURMOUNT-1 and SURMOUNT-3, participants from multiple countries were randomly assigned to tirzepatide or placebo for 72 weeks. In SURMOUNT-CN, participants were assigned to tirzepatide or placebo for 52 weeks and were enrolled exclusively from China.
All SURMOUNT trials enrolled participants with overweight or obesity without diabetes.
As Healio previously reported, in SURMOUNT-1, almost all participants assigned to tirzepatide experienced 5% or more weight loss over 72 weeks vs. placebo, with at least 20% weight loss in more than half of participants receiving the highest dose. In SURMOUNT-3, participants assigned to tirzepatide for 72 weeks following a 12-week intensive lifestyle intervention achieved a mean weight loss of more than 24%.
The results of SURMOUNT-CN were published in JAMA in 2024. In that trial, the proportion of participants who achieved weight reductions of 5% or more was 87.7% among those assigned to tirzepatide 10 mg, 85.8% among those assigned to tirzepatide 15 mg and 29.3% of those assigned to placebo.
For the present analysis, researchers pooled data from the three SURMOUNT trials to evaluate the impact of achieving BMI of less than 25 kg/m2 on 10-year ASCVD risk as calculated by the American Heart Association/American College of Cardiology Pooled Cohort Equations.
Among the cohort of 2,691 participants (mean age,45 years; 66% women),18.4% achieved BMI of less than 25 kg/m2 at trial end.
participants who achieved a BMI of less than 25 kg/m2 were more frequently enough assigned to tirzepatide (98.2% vs. 66.8%), more often women (79.6% vs. 63.4%) and with lower mean BMI at baseline compared with those whose BMI remained above 25 kg/m2 at trial end (32.3 kg/m2 vs. 38.2 kg/m2; P for all < .001).
After adjusting for baseline covariates, participants who achieved a BMI of less than 25 kg/m2 experienced
Okay, I will analyze the provided HTML snippet and follow the three-phase process as instructed.
PHASE 1: ADVERSARIAL RESEARCH,FRESHNESS & BREAKING-NEWS CHECK
The HTML snippet relates to a subscription form for email notifications about articles on a specific topic within the "Healio" platform. The topic itself is not specified in the snippet,only represented by the placeholder .The error message references , which is unusual given Healio is a healthcare news platform. This is a potential red flag.
* Slack inc.: Slack is a business communication platform. https://slack.com/intl/en-us/ The use of a Slack customer service email for a Healio issue is highly suspect.
* Email Subscription: The functionality described (email notifications for new articles) is a common feature on news and content platforms.
Breaking News Check (as of 2026/01/17 08:15:13):
There are no breaking news events directly related to the functionality of an email subscription service. However, a search reveals that Healio was acquired by MJH Life Sciences in 2023. https://www.healio.com/news/industry/20230926/mjh-life-sciences-acquires-healio. This is relevant as it impacts the ownership and perhaps the contact information for customer service. The use of a Slack email address in the error message is even more concerning considering this acquisition.
Latest Verified Status: Healio is currently owned by MJH Life Sciences. The customer service contact provided in the snippet () appears to be incorrect and outdated.
PHASE 2: ENTITY-BASED GEO (GENERATIVE ENGINE OPTIMIZATION)
* slack Inc.: The company whose email address is incorrectly listed for customer support. https://slack.com/intl/en-us/
* Healthcare Industry: The broad industry Healio serves.
* Specific Medical Specialties: (Dependent on the topic – e.g., cardiology, Oncology, etc.)
Healio is a multi-specialty healthcare news and information resource providing medical professionals with the latest clinical updates, peer-reviewed research, and expert insights. learn more about Healio.
In September 2023, Healio was acquired by MJH Life Sciences, a leading medical communications company. Read the official announcement. This acquisition has likely impacted operational aspects of Healio, including customer support.
Healio offers users the ability to subscribe to email notifications for new articles published on specific topics of interest. This allows healthcare professionals to stay informed about the latest developments in their fields.
The error message within the subscription form incorrectly lists [email protected] as the contact for support. Given the acquisition by MJH Life Sciences,and the fact that Slack is a separate entity,this contact is highly likely outdated.Users experiencing issues should seek current contact information on the Healio Contact Page.
* Definition / Direct Answer: healio is a comprehensive, multi-specialty healthcare news and information resource designed for medical professionals.
* Detail: Healio provides access to peer-reviewed research, clinical updates, and expert commentary across a wide range of medical specialties. It aims to keep healthcare providers informed about the
